Description
A dicaffeoyl ester with diverse biological activities; reduces the viability of Caco-2 and HCT116 colorectal cancer cells from 50-200 μg/ml; inhibits the 3′-processing and DNA integration activities of HIV integrase (IC50s = 1.1 and 0.8 μM, respectively); inhibits HIV entry into H9 cells at 5 μM; oral administration reduces hepatic lipid accumulation, lipid peroxidation, and fibrosis, inhibits production of pro-inflammatory cytokines and activation of NF-kB, and activates the AMPK signaling pathway in a mouse model of NASH induced by a methionine and choline-deficient diet at 10 and 30 mg/kg; reduces blood glucose levels by 54% in mice with streptozotocin-induced diabetes at 2 mg/kg
Formal name: (2R,3R)-2,3-bis[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-butanedioic acid
Synonyms: Dicaffeoyltartaric Acid|L-Chicoric Acid|NSC 99173
Molecular weight: 474.4
CAS: 70831-56-0
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|Integrase Inhibitors||Product Type|Biochemicals|Natural Products||Product Type|Biochemicals|Ox Stress Reagents|Antioxidants||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer|Cell Death||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS
